Evidence map›Paper›PMID 39451245›Full record

ArticleCells2024

Hymecromone Promotes Longevity and Insulin Sensitivity in Mice.

Nadine Nagy, Kathryn S Czepiel, Gernot Kaber, Darko Stefanovski, Aviv Hargil, Nina Pennetzdorfer, Robert Targ, Saranya C Reghupaty, Thomas N Wight, Robert B Vernon and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Nadine NagyDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-2638-2436
Kathryn S CzepielDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Gernot KaberDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Darko StefanovskiDepartment of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348, USA.
Aviv HargilDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Nina PennetzdorferDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Robert TargDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Saranya C ReghupatyDepartment of Pathology, School of Medicine, Stanford University, Stanford, CA 94305, USA.
Thomas N WightBenaroya Research Institute, 1201 9th Ave, Seattle, WA 98101, USA.
Robert B VernonBenaroya Research Institute, 1201 9th Ave, Seattle, WA 98101, USA.
Rebecca L Hull-MeichleDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA 98108, USA.
Payton MarshallDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Carlos O MedinaDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0002-8324-7994
Hunter MartinezDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
Anissa KalinowskiHalo Biosciences, 125 University St., Palo Alto, CA 94301, USA.ORCID 0000-0003-3298-5580
Rudolph D PaladiniHalo Biosciences, 125 University St., Palo Alto, CA 94301, USA.
Stavros GarantziotisImmunity, Inflammation and Disease Laboratory, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.ORCID 0000-0003-4007-375X
Joshua W KnowlesCardiovascular Medicine and Cardiovascular Institute, School of Medicine, Stanford University, Stanford, CA 94305, USA.ORCID 0000-0003-1922-7240
Paul L BollykyDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
MOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0M
Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Tissue Cytokine Sequestration and Immune Regulation in AutoimmunityU01AI101984 · NIAID · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2021
$5.0M
Lymph Node Extracellular Matrix in Antigen Presentation and Immune RegulationR01DK096087 · NIDDK · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2021
$3.4M
Characterization of novel insulin resistance genes by gene editing, high-throughput phenotyping and in vivo studiesR01DK120565 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$3.2M
Mechanisms of NAT2 Regulation of Insulin Resistance and Mitochondrial DysfunctionR01DK116750 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$2.4M
The Stanford Clinical Center for the Study of Type 1 Diabetes in Acute PancreatitisU01DK127395 · NIDDK · STANFORD UNIVERSITY · PI Marina Basina, Walter Gwang-Up Park · 2020 to 2026
$2.2M
ECM Costimulation of Immunoregulatory Pathways in Airway InflammationR01HL113294 · NHLBI · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2016
$2.0M
The Role of Hyaluronan and CD44 in the Pathogenesis of Type 2 DiabetesR01DK116782 · NIDDK · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2020 to 2023
$1.6M
NHLBI NIH HHS R01 HL113294NIAID NIH HHS T32 AI007290NIAID NIH HHS U01 AI101984NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK096087NIDDK NIH HHS R01 DK116750NIDDK NIH HHS R01 DK116782NIDDK NIH HHS R01 DK120565NIDDK NIH HHS U01 DK127395NIH HHS R01 DK096087-01NIH HHS R01 HL113294-01A1NIH HHS U01 AI101984
6 · The paper itself

Abstract

Given that the extracellular matrix polymer hyaluronan (HA) has been implicated in longevity, we asked whether 4-methylumbelliferone (4-MU), an inhibitor of HA synthesis, impacts lifespan in mice. We designed a prospective study of long-term administration of 4-MU with conventional C57BL/6J mice. We find that 4-MU extends median survival from 122 weeks (control) to 154 weeks (4-MU), an increase of 32 weeks (

Indexed as

HymecromoneInsulin ResistanceLongevityMice, Inbred C57BLAnimalsGlucose Tolerance TestHyaluronic AcidInsulinMaleMiceHyaluronic AcidHymecromoneInsulinglycemic controlhyaluronanhymecromoneinsulin resistancelongevity

Identifiers

PMID39451245
PMCPMC11506560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.